If the FDA is happy with daprodustat's safety profile and approves the drug, it will help GSK meet its target of £500 million to £1 billion ($650 million to $1.3 billion) in sales for the drug ...

GSK has said that its daprodustat for anaemia associated ... clinical trial to bolster the data for the drug, although it was subsequently approved in the EU. Meanwhile, it concluded vadadustat ...